Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464059 · ClinicalTrials.gov registry record · Phase 2
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT02464059 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 23 participants, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02464059, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this application would also provide the justification to study vitamin D as a therapy to improve lung health.
Conditions Studied
Interventions
- DRUG Vitamin D3
Study Locations (2)
Maryland
- Johns Hopkins Clinical Research Unit - Baltimore
North Carolina
- Meadowmont Pulmonary Research Clinic - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2020-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464059
The ClinicalTrials.gov registry entry for NCT02464059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (98% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT02464059 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02464059 about?
NCT02464059 is a clinical study titled "Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD". This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this ...
What is the current status of trial NCT02464059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2015-11-10. Estimated completion is 2020-04-15.
What conditions does trial NCT02464059 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT02464059?
The interventions under investigation include: Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT02464059?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02464059 being conducted?
This trial has 2 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
-
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.